Business Context and Reporting Period
Company: Anixa Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 9, 2026
Reporting Period: Single event date (February 9, 2026)
Business Context: The filing discloses a significant clinical development update regarding the Company's Phase 1 clinical trial for an ovarian cancer CAR-T therapy.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Clinical Trial Progress: Encouraging patient survival data was observed in the Phase 1 clinical trial for the Company's ovarian cancer CAR-T therapy.
- Regulatory Approval: Regulatory approval was granted to enable dose escalation in the trial beyond the doses originally set forth in the trial protocol.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (Exhibit 99.1) highlighting the positive survival data and the regulatory green light for dose escalation.
Forward-Looking Statements: The filing contains forward-looking statements regarding future clinical trial results and regulatory outcomes. These are based on current expectations and involve significant risks and uncertainties.
Risks and Contingencies: Actual results may differ materially from expectations due to factors beyond the Company's control. Investors are directed to "Item 1A - Risk Factors" in the most recent Form 10-K and subsequent 10-Q and 8-K filings for a detailed list of risks.
Investor Verification Checklist
- Review the full text of the press release filed as Exhibit 99.1 for specific details on the survival data metrics.
- Verify the specific regulatory body that granted the dose escalation approval.
- Examine the "Risk Factors" section of the most recent Form 10-K to understand potential clinical trial failures or regulatory hurdles.
- Confirm the timeline for the next phase of the trial or subsequent data readouts.